SCHEMBL3940148

SCHEMBL3940148

Cc1ccc(C(=O)NCCc2ccc(Cl)c(Cl)c2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.65
NPC1 O15118 3/20 0.62
RAB9A P51151 3/20 0.62
SMN1; SMN2 Q16637 2/20 0.59
KMT2A Q03164 2/20 0.59
ESRRG P62508 1/20 0.57
GAA P10253 2/20 0.55
LMNA P02545 2/20 0.54
TP53 P04637 1/20 0.54
ALDH1A1 P00352 2/20 0.54
HPGD P15428 2/20 0.54
POLB P06746 2/20 0.54
HTT P42858 2/20 0.54
MAPT P10636 3/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C19 P33261 1/20 0.54
GFER P55789 1/20 0.54
LIPG Q9Y5X9 1/20 0.53
PTGDR2 Q9Y5Y4 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3573110 0.85 TRPV1 (0.64) TRPV1NPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL7616443 0.85 LMNA (0.65) SMN1; SMN2KMT2ALMNAALDH1A1HPGD
SCHEMBL3391330 0.85 TRPV1 (0.65) TRPV1NPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL14469162 0.85 NPC1 (0.84) NPC1RAB9ASMN1; SMN2KMT2AESRRG
SCHEMBL5176124 0.83 TRPV1 (0.62) TRPV1NPC1RAB9ASMN1; SMN2ESRRG
SCHEMBL1386961 0.81 TRPV1 (0.70) TRPV1NPC1RAB9ASMN1; SMN2ESRRG
SCHEMBL5175816 0.80 TRPV1 (0.69) TRPV1NPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL5176430 0.80 TRPV1 (0.68) TRPV1NPC1RAB9ASMN1; SMN2ESRRG
SCHEMBL11207410 0.80 PLAAT3 (0.62) TRPV1SMN1; SMN2HPGDLIPG
SCHEMBL3018128 0.80 HDAC6 (0.61) TRPV1NPC1RAB9AKMT2AESRRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090171091-A1 COMPOUNDS SUITABLE AS MODULATORS OF HDL CADILA HEALTHCARE LIMITED (IN) 2009-07-02 US claimed
EP-2049493-A2 COMPOUNDS SUITABLE AS MODULATORS OF HDL Cadila Healthcare Limited (IN) 2009-04-22 EP claimed
WO-2008059513-A2 COMPOUNDS SUITABLE AS MODULATORS OF HDL CADILA HEALTHCARE LIMITED (IN) 2008-05-22 WO claimed
US-20090171091-A1 COMPOUNDS SUITABLE AS MODULATORS OF HDL CADILA HEALTHCARE LIMITED (IN) 2009-07-02 US disclosed
EP-2049493-A2 COMPOUNDS SUITABLE AS MODULATORS OF HDL Cadila Healthcare Limited (IN) 2009-04-22 EP disclosed
WO-2008059513-A2 COMPOUNDS SUITABLE AS MODULATORS OF HDL CADILA HEALTHCARE LIMITED (IN) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090171091-A1 COMPOUNDS SUITABLE AS MODULATORS OF HDL CETP, APOB, HDLBP TRPV1 3452/4885NPC1 11/4885RAB9A 2262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.